Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...

Their results underscore the importance of early detection and treatment, such as with vorasidenib, which targets IDH and was recently approved by the FDA for low-grade gliomas. The study also ...

Henry Friedman, a deputy director at the Preston Robert Tisch Brain Tumor Center at Duke University, tells SurvivorNet it’s a ...

Firefighters show higher rates of glioma-linked SBS42 mutational signatures associated with haloalkane exposure, suggesting ...

New research by Yale has found an association between exposure to chemicals commonly used in firefighting and incidence of a ...

The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by ...

UCLA co-led study is first trial analyzing a targeted therapy drug specifically made for brain tumors. In an international study co-led by UCLA Health Jonsson Comprehensive Cancer Center ...

The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this aggressive ...

advances in molecular biology are delineating the heterogeneity of the rare anaplastic gliomas, leading to an improved understanding of the prognostic importance of chromosome 1p19q deletion, IDH ...